InspireMD to Return to US Market and Undergo Strategic Pivot Following FDA Approval
NSPR InspireMD Inc
$0.77 -3.25%
View chart & analysis → - 1InspireMD has received FDA approval for the CGuard Prime TransCarotid stent system.
- 2The company implemented a 20% reduction in InspireMD workforce during the third quarter to reduce operating costs.
- 3In the third quarter of 2026, InspireMD's international revenue, which recorded a 9% year-over-year growth rate, was $2.2 million.
So what's the key point?
InspireMD received US medical device approval. The company managed operating costs by reducing its workforce by 20% and recorded $2.2 million in international revenue.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.